1. The alpha-2 adrenergic autoreceptor on sympathetic nerve terminals functions as a critical negative feedback regulator of NE release. Which of the following most accurately describes this autoreceptor mechanism and identifies the drugs that exploit it therapeutically?

• A) Alpha-2 autoreceptors are located on the postsynaptic effector cell membrane and detect accumulation of NE in the synapse -- when activated, they signal back to the presynaptic terminal via a retrograde messenger (nitric oxide) to reduce vesicular exocytosis; yohimbine blocks this retrograde signaling pathway, preventing autoreceptor-mediated feedback inhibition and increasing NE release; this mechanism explains yohimbine's use as a sympathomimetic and aphrodisiac.
• B) Presynaptic alpha-2 autoreceptors are Gi-coupled receptors located on the sympathetic nerve terminal membrane; when activated by NE that has accumulated in the synapse, they inhibit adenylyl cyclase (reducing cAMP), open inhibitory potassium channels (hyperpolarizing the terminal), and close presynaptic N-type calcium channels (reducing calcium-triggered exocytosis) -- collectively reducing further NE release in a classic negative feedback loop; clonidine activates these presynaptic alpha-2 receptors (and postsynaptic alpha-2 receptors in the brainstem NTS/RVLM) to reduce sympathetic outflow; yohimbine blocks alpha-2 autoreceptors, disinhibiting NE release and increasing sympathetic tone.
• C) Alpha-2 autoreceptors are located on the sympathetic nerve terminal and when activated by NE, they stimulate adenylyl cyclase via Gs coupling to increase cAMP -- the resulting PKA activation phosphorylates synapsin, mobilizing vesicles from the reserve pool to the readily releasable pool and paradoxically increasing NE release; this positive feedback mechanism explains why sympathetic stimulation produces self-amplifying NE release rather than a self-limiting response.
• D) Presynaptic alpha-2 autoreceptors are Gq-coupled and when activated produce IP3-mediated calcium release from the smooth endoplasmic reticulum of the nerve terminal -- this intraterminal calcium surge paradoxically triggers a burst of exocytosis followed by vesicle depletion; the net effect is an initial increase followed by prolonged reduction in NE release; drugs that block alpha-2 autoreceptors (mirtazapine) therefore produce an initial sympathomimetic burst that explains the tachycardia sometimes seen at treatment initiation.
• E) Alpha-2 autoreceptors do not regulate NE release at the sympathetic neuroeffector junction -- they are expressed exclusively at central adrenergic synapses in the locus coeruleus and RVLM, where they regulate central NE neuron firing rate; peripheral sympathetic terminals lack presynaptic autoreceptors, and NE release at peripheral neuroeffector junctions is regulated solely by the frequency of action potential firing from the CNS.

2. Neuromuscular transmission at the skeletal muscle motor end plate involves a sequence of molecular events that are each potential drug targets. Which of the following most accurately describes the sequence from action potential arrival to muscle contraction, and correctly identifies where botulinum toxin and succinylcholine act within this sequence?

• A) Action potential arrives at the motor nerve terminal -> voltage-gated N-type calcium channels open -> calcium influx triggers SNARE-mediated vesicular exocytosis of ACh -> ACh diffuses across the synaptic cleft -> ACh binds NM nicotinic receptors (pentameric: 2 alpha1, beta1, delta, epsilon/gamma) -> ion channel opens, Na+ influx produces end plate potential -> end plate potential triggers muscle action potential -> T-tubule L-type calcium channels activate ryanodine receptors -> calcium-induced calcium release from SR -> troponin C binding -> actin-myosin cross-bridge formation -> contraction; botulinum toxin cleaves SNARE proteins (SNAP-25, synaptobrevin/VAMP, or syntaxin depending on serotype), preventing vesicular fusion and ACh release; succinylcholine is a depolarizing NM agonist that produces initial fasciculations (phase 1 block from sustained depolarization keeping sodium channels inactivated) followed by flaccid paralysis.
• B) Action potential arrives at the motor nerve terminal -> voltage-gated L-type calcium channels open -> calcium influx triggers clathrin-mediated endocytosis of ACh-containing vesicles for redistribution to the active zone -> redistribution triggers constitutive ACh leakage into the cleft -> ACh binds NM receptors -> succinylcholine competitively blocks ACh at NM receptors (non-depolarizing mechanism) producing flaccid paralysis; botulinum toxin activates voltage-gated calcium channels, producing sustained calcium influx and tetanic ACh release that exhausts vesicular stores and produces a depletion paralysis.
• C) Botulinum toxin is a zinc-dependent metalloprotease that cleaves specific SNARE proteins required for vesicular docking and fusion at the motor nerve terminal -- different botulinum serotypes cleave different SNARE proteins (type A and E cleave SNAP-25; types B, D, F, G cleave synaptobrevin/VAMP; type C cleaves both syntaxin and SNAP-25); cleavage prevents ACh vesicle fusion with the presynaptic membrane and abolishes ACh release, producing flaccid paralysis with intact sensation; succinylcholine mimics ACh at NM receptors but is hydrolyzed slowly by plasma cholinesterase (pseudocholinesterase) rather than AChE, producing prolonged depolarization of the end plate that keeps voltage-gated sodium channels in the inactivated state and prevents further action potential generation in the muscle -- a depolarizing block.
• D) The action potential at the motor nerve terminal opens voltage-gated potassium channels exclusively, producing an outward potassium current that directly drives vesicular exocytosis by a potassium-calcium exchange mechanism -- blocking voltage-gated potassium channels with aminopyridines (3,4-DAP) therefore prevents ACh release by eliminating the exocytosis-driving potassium current; botulinum toxin activates these potassium channels prematurely, preventing depolarization-triggered exocytosis; succinylcholine blocks NM receptors by steric occlusion of the ion channel pore without producing end plate depolarization.
• E) Succinylcholine and botulinum toxin produce identical clinical paralysis through different molecular mechanisms -- succinylcholine cleaves SNARE proteins to prevent ACh release while botulinum toxin acts as a depolarizing NM agonist; the distinction is clinically important because succinylcholine paralysis is reversible with neostigmine (which restores ACh release by inhibiting AChE) while botulinum toxin paralysis is irreversible regardless of AChE inhibitor administration.

3. The calcium dependence of neurotransmitter release at autonomic synapses and the neuromuscular junction is exploited by several toxins and drugs. Which of the following most accurately describes how calcium triggers vesicular exocytosis and identifies agents that disrupt this calcium-exocytosis coupling?

• A) Calcium triggers neurotransmitter release by binding to calmodulin on the inner surface of the presynaptic membrane -- the calcium-calmodulin complex activates myosin light chain kinase, which phosphorylates synapsin I, detaching vesicles from the actin cytoskeleton and allowing them to move to the active zone; omega-conotoxin (from cone snails) blocks this calmodulin-calcium step by competitive displacement of calcium from its calmodulin binding site; Lambert-Eaton syndrome autoantibodies target calmodulin rather than calcium channels, explaining the proximal muscle weakness pattern.
• B) Calcium triggers neurotransmitter release at autonomic synapses primarily through the IP3 receptor on the smooth endoplasmic reticulum -- presynaptic action potentials activate phospholipase C via a Gq-coupled presynaptic receptor, generating IP3 that releases calcium from ER stores rather than from the extracellular space; this IP3-mediated calcium release is the primary exocytosis trigger at most synapses; drugs that deplete ER calcium stores (thapsigargin) block neurotransmitter release by this presynaptic IP3 mechanism.
• C) Action potential-triggered calcium influx through voltage-gated N-type (Cav2.2) and P/Q-type (Cav2.1) calcium channels at presynaptic active zones binds synaptotagmin (the calcium sensor on synaptic vesicles) -- synaptotagmin-calcium binding releases the inhibitory clamp on the SNARE complex (syntaxin-1A/SNAP-25/synaptobrevin), allowing rapid membrane fusion and exocytosis within microseconds; omega-conotoxin GVIA blocks N-type calcium channels (disrupting autonomic synaptic transmission); omega-agatoxin blocks P/Q-type channels (disrupting NMJ transmission); Lambert-Eaton myasthenic syndrome autoantibodies target P/Q-type (Cav2.1) channels at the NMJ, reducing calcium influx and impairing ACh release.
• D) Calcium triggers exocytosis by directly inserting into the lipid bilayer of the synaptic vesicle membrane, changing its surface charge and causing spontaneous membrane fusion with the active zone plasma membrane in a protein-independent manner -- drugs that chelate extracellular calcium (EGTA, EDTA) block neurotransmitter release by preventing calcium from reaching the vesicle membrane; magnesium sulfate (used in eclampsia) blocks neurotransmitter release by competing with calcium for its membrane insertion sites on synaptic vesicles.
• E) Calcium channels at presynaptic terminals are exclusively R-type (Cav2.3) throughout the autonomic nervous system and neuromuscular junction -- N-type and P/Q-type calcium channels are expressed only in central nervous system synapses; this peripheral-central distinction in calcium channel subtype explains why ziconotide (omega-conotoxin MVIIA, an N-type calcium channel blocker used intrathecally for chronic pain) produces central analgesia without affecting peripheral autonomic transmission or neuromuscular function.

4. Organophosphate compounds produce their toxic and therapeutic effects through the same mechanism -- irreversible inhibition of acetylcholinesterase. Which of the following most accurately predicts the complete clinical syndrome of severe organophosphate toxicity and explains the pharmacological rationale for the two-drug antidotal regimen?

• A) Organophosphate toxicity produces a pure sympathomimetic syndrome because organophosphates irreversibly inhibit both AChE and MAO simultaneously -- the MAO inhibition prevents NE degradation while the AChE inhibition provides nicotinic stimulation of the adrenal medulla, producing combined catecholamine excess and nicotinic receptor activation; treatment is with alpha and beta-adrenergic blockers (labetalol) combined with nicotinic ganglionic blockers (trimethaphan) to address both components of the toxidrome.
• B) Organophosphate toxicity produces cholinergic crisis from ACh accumulation at all cholinergic synapses simultaneously: muscarinic effects (SLUDGE/DUMBELS: salivation, lacrimation, urination, defecation, GI distress, emesis; bradycardia, bronchospasm, bronchorrhea, miosis); nicotinic NM effects (muscle fasciculations progressing to flaccid paralysis from persistent depolarization block); nicotinic NN effects at ganglia (initial stimulation then block); and central effects (seizures, coma from CNS ACh accumulation); treatment uses atropine (to block muscarinic effects, particularly bronchospasm and bronchorrhea -- the life-threatening components) in high doses until bronchial secretions dry, PLUS pralidoxime (2-PAM) given early before aging of the organophosphate-AChE bond to regenerate functional AChE and address nicotinic NM effects not reversed by atropine.
• C) Organophosphate toxicity produces isolated nicotinic toxicity at the neuromuscular junction (fasciculations, weakness, paralysis) without any muscarinic effects, because the synaptic cleft concentration of ACh required to activate muscarinic receptors at autonomic neuroeffector junctions is much higher than the NM junction concentration -- treatment is with pralidoxime alone, since atropine would worsen the nicotinic effects by blocking presynaptic muscarinic autoreceptors that normally limit ACh release.
• D) The antidotal regimen for organophosphate toxicity is atropine (competitive muscarinic antagonist reversing SLUDGE syndrome, bronchospasm, and bradycardia) plus pralidoxime (2-PAM), a nucleophilic oxime that attacks the phosphorus-serine bond of the organophosphate-AChE adduct, regenerating functional AChE before the adduct undergoes aging (loss of a leaving group that renders the bond irreversible) -- pralidoxime must be given within hours of exposure because aged organophosphate-AChE complexes cannot be reactivated; benzodiazepines (diazepam) are added for seizure control since atropine does not adequately suppress central cholinergic seizures; atropine doses required in severe poisoning (tens to hundreds of milligrams) far exceed routine clinical doses and are titrated to drying of bronchial secretions.
• E) Organophosphate toxicity produces a biphasic syndrome: initial parasympathomimetic phase (from muscarinic ACh excess) followed by delayed sympathomimetic phase (from catecholamine release triggered by ganglionic nicotinic stimulation of the adrenal medulla) -- treatment in the sympathomimetic phase requires adding beta-blockers to the atropine/pralidoxime regimen to control the adrenomedullary catecholamine surge; failure to recognize the biphasic nature of organophosphate toxicity leads to inadequate treatment of the late sympathomimetic component.

5. The phenomenon of presynaptic autoreceptor-mediated feedback differs importantly between adrenergic and cholinergic synapses. In cholinergic autonomic ganglia and the neuromuscular junction, muscarinic autoreceptors modulate ACh release. Which of the following most accurately describes this presynaptic muscarinic autoreceptor system and its pharmacological implications?

• A) Cholinergic nerve terminals in autonomic ganglia express presynaptic M2 muscarinic autoreceptors -- when activated by synaptically released ACh, these Gi-coupled M2 receptors inhibit adenylyl cyclase, activate inhibitory potassium channels, and reduce presynaptic calcium entry, limiting further ACh release; at the neuromuscular junction, presynaptic M1 receptors facilitate ACh release during high-frequency stimulation; atropine (non-selective muscarinic antagonist) blocks both M2 autoreceptors (disinhibiting ACh release) and M1 facilitatory receptors (reducing release during tetanic stimulation), with the net effect at therapeutic doses being primarily the removal of M2-mediated inhibition, potentially increasing ganglionic ACh release.
• B) Cholinergic nerve terminals express presynaptic M2 muscarinic autoreceptors that inhibit ACh release through Gi-coupled inhibition of adenylyl cyclase and activation of inwardly rectifying potassium channels -- this negative feedback limits ACh accumulation during prolonged or high-frequency stimulation; at the neuromuscular junction, presynaptic muscarinic receptors modulate the safety factor of transmission during repetitive stimulation; atropine blocks presynaptic M2 autoreceptors, removing the inhibitory feedback and increasing ACh release -- an effect that contributes to atropine's ability to partially counteract certain aspects of non-depolarizing NM block, independent of its primary muscarinic antagonism at effector organs.
• C) Cholinergic presynaptic autoreceptors in autonomic ganglia are exclusively nicotinic (NN) rather than muscarinic -- the positive feedback from NN autoreceptor activation during sustained ACh release amplifies ganglionic transmission during high-frequency sympathetic activation; muscarinic autoreceptors exist only in the CNS at hippocampal cholinergic synapses; atropine has no effect on ganglionic ACh release because it is a muscarinic antagonist that does not act on the presynaptic nicotinic autoreceptors responsible for modulating ganglionic ACh release.
• D) Presynaptic muscarinic autoreceptors at cholinergic terminals are M3 subtype -- when activated by ACh they stimulate phospholipase C via Gq, generating IP3-mediated calcium release from presynaptic ER stores that paradoxically increases further ACh exocytosis; this positive feedback mechanism is the basis for the clinical observation that atropine (an M3 antagonist at presynaptic sites) reduces total ACh release and can partially reverse the fasciculations of early organophosphate toxicity by reducing presynaptic positive feedback.
• E) Cholinergic synapses lack presynaptic autoreceptors entirely -- acetylcholinesterase in the synaptic cleft provides the sole feedback mechanism limiting ACh accumulation; the rapid enzymatic hydrolysis of ACh (half-life approximately 1 millisecond in the cleft) is sufficient to prevent ACh accumulation between action potentials even during high-frequency stimulation; this is why AChE inhibitors (neostigmine, physostigmine) are effective treatments for myasthenia gravis -- they restore functional transmission without requiring any presynaptic regulatory mechanism.